Search

Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

Pulmonary Fibrosis

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis 

Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer

Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF™ study

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.

Lung Diseases

Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration

New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype

OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)

OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)

New partnership in Alberta supports healthcare solutions for interstitial lung diseases

New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD

Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support

Burlington, ON (October 25, 2023) – In a unique partnership, Boehringer Ingelheim (Canada) Ltd., St. Joseph's Healthcare Hamilton, and McMaster University have come together to transform the way patients are supported at the onset of a diagnosis

Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

Pulmonary Fibrosis

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Lung Diseases

Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration

New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype

OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)

OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

New partnership in Alberta supports healthcare solutions for interstitial lung diseases

New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD

Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support

Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis 

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD